The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin

Esophageal cancer is the ninth most common malignancy worldwide, ranking sixth in mortality. Platinum-based chemotherapy commonly used for treating locally advanced esophageal cancer, yet it ineffective a large portion of patients. There need reliable molecular markers with direct clinical application prospective selection patients who can benefit from and whom toxicity likely to outweigh benefit. The cytotoxic activity platinum derivatives largely depends on uptake accumulation into cells, primarily by organic cation transporters (OCTs). aim study was investigate impact OCT expression outcome treated oxaliplatin. Twenty squamous cell carcinoma (SCC) were prospectively enrolled surgical specimens screening level western blotting and/or immunostaining, culture cells. Sixty-seven SCC received oxaliplatin follow-up available retrospectively assessed cation/carnitine transporter 2 (OCTN2) real time RT-PCR immunostaining. OCTN2 staining also performed 22 adenocarcinomas. function patient-derived cells evaluated assessing L-carnitine sensitivity HEK293 overexpressing OCTN2. higher tumor than normal tissues. In sensitized Patients had high tissue reduced risk recurrence longer survival those low tissue. conclusion, expressed contribute